Free tool
FAERS Monitor: Omnitrope
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021426 or its brand name (Omnitrope, Somatropin). Reports on generic versions are filed under their own applications.
Reports
17,867
Serious
7,443
42% of reports
Hospitalization
2,489
Death reported
536
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain1,811
- device breakage1,690
- device leakage1,631
- incorrect dose administered1,143
- incorrect dose administered by device1,140
- device issue963
- circumstance or information capable of leading to medication error922
- product dose omission issue913
- drug dose omission by device822
- headache814
- circumstance or information capable of leading to device use error690
- injection site haemorrhage643
- off label use634
- injection site bruising599
- device mechanical issue596
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 13 |
| 2006 | 26 |
| 2007 | 110 |
| 2008 | 47 |
| 2009 | 216 |
| 2010 | 169 |
| 2011 | 216 |
| 2012 | 233 |
| 2013 | 162 |
| 2014 | 231 |
| 2015 | 495 |
| 2016 | 1,022 |
| 2017 | 915 |
| 2018 | 1,245 |
| 2019 | 1,114 |
| 2020 | 1,000 |
| 2021 | 903 |
| 2022 | 1,068 |
| 2023 | 1,661 |
| 2024 | 2,254 |
| 2025 | 3,307 |
| 2026 | 1,421 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,292 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| circumstance or information capable of leading to device use errorSignal | 690 | 481.8 | 441.5 | 234,629 |
| incorrect dose administered by deviceSignal | 1,140 | 53.5 | 50.5 | 56,179 |
| device mechanical issueSignal | 596 | 53.5 | 49.3 | 29,313 |
| device breakageSignal | 1,690 | 51.1 | 48.8 | 79,652 |
| device leakageSignal | 1,631 | 46.0 | 43.9 | 69,157 |
| circumstance or information capable of leading to medication errorSignal | 922 | 33.0 | 31.0 | 27,850 |
| device issueSignal | 963 | 12.8 | 12.0 | 10,364 |
| drug dose omission by deviceSignal | 822 | 12.5 | 11.7 | 8,608 |
| injection site haemorrhageSignal | 643 | 9.5 | 8.8 | 4,890 |
| injection site bruisingSignal | 599 | 8.9 | 8.2 | 4,176 |
| injection site painSignal | 1,811 | 7.0 | 6.7 | 9,364 |
| incorrect dose administeredSignal | 1,143 | 5.9 | 5.6 | 4,695 |
| product dose omission issueSignal | 913 | 3.7 | 3.4 | 1,785 |
| headache | 814 | 1.5 | 1.4 | 153 |
| off label use | 634 | 0.9 | 0.8 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.